Steven Cohen Hille Vax, Inc. Transaction History

Point72 Asset Management, L.P.

  • $36.6 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$11.86 - $15.93 $5.71 Million - $7.67 Million
481,312 New
481,312 $6.96 Million
Q1 2023

May 15, 2023
BUY
$14.73 - $18.18 $144,412 - $178,236
9,804 New
9,804 $162,000
Q2 2022

Aug 15, 2022
BUY
$8.7 - $20.18 $130,499 - $302,700
15,000 New
15,000 $164,000

Others Institutions Holding HLVX

# of Institutions
80
Shares Held
36.8M
Call Options Held
0
Put Options Held
0
View Full List

About HilleVax, Inc.

HLVX Quotes by TradingView
  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $66.9M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email